Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 19992008 and treated with curative intent in the AIDS Malignancy Consortium

Ulas D. Bayraktar, Juan Carlos Ramos, Adam Petrich, Neel Gupta, Shelly Lensing, P. C. Moore, Erin G. Reid, David M. Aboulafia, Lee Ratner, Ronald Mitsuyasu, Timothy Cooley, David H. Henry, Paul Barr, Ariela Noy

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

No comparative studies exist for relapsed/refractory (rel/rfr) acquired immune deficiency syndrome (AIDS)-related lymphoma (ARL). To determine practices over the last decade and to assess the outcomes of salvage chemotherapy with curative intent and autologous stem cell transplant (ASCT), we retrospectively evaluated treatment outcomes in patients with rel/rfr ARL who were treated in 13 national AIDS Malignancy Consortium (AMC) sites between 1999 and 2008 (n 88). The most commonly used second-line therapies were ICE (ifosfamide/carboplatin/ etoposide, n 34), dose adjusted EPOCH (etoposide/prednisone/vincristine/ cyclophosphamide/doxorubicin, n 17) and ESHAP (etoposide/methylprednisolone/ cytarabine/cisplatin, n 11). The odds of achieving a response were lower for those with non-Hodgkin lymphoma (NHL) than for those with HL and for those with primary refractory disease than for those with relapse. Overall survival (OS) was significantly longer for those with relapsed disease compared to those with refractory disease and for those with non-Burkitt NHL compared to those with Burkitt. OS was longer in patients who underwent ASCT compared to those who did not (1-year OS: 63.2% vs. 37.2%). However, among 32 patients (36%) who achieved a complete or partial reponse (CR/PR) after second-line therapy, 1-year OS was not different between the two groups (87.5% for ASCT vs. 81.8% for non-ASCT). Long-term survival in some patients with rel/rfr ARL may be possible without transplant, although transplant remains the standard of care for chemotherapy sensitive disease.

Original languageEnglish
Pages (from-to)2383-2389
Number of pages7
JournalLeukemia and Lymphoma
Volume53
Issue number12
DOIs
StatePublished - Dec 1 2012

Fingerprint

Lymphoma
Acquired Immunodeficiency Syndrome
Transplants
Etoposide
Stem Cells
AIDS-Related Lymphoma
Survival
Neoplasms
Non-Hodgkin's Lymphoma
Drug Therapy
Ifosfamide
Carboplatin
Cytarabine
Methylprednisolone
Vincristine
Standard of Care
Prednisone
Doxorubicin
Cyclophosphamide
Cisplatin

Keywords

  • Acquired immune deficiency syndrome
  • Lymphoma
  • Salvage therapy
  • Stem cell transplant

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 19992008 and treated with curative intent in the AIDS Malignancy Consortium. / Bayraktar, Ulas D.; Carlos Ramos, Juan; Petrich, Adam; Gupta, Neel; Lensing, Shelly; Moore, P. C.; Reid, Erin G.; Aboulafia, David M.; Ratner, Lee; Mitsuyasu, Ronald; Cooley, Timothy; Henry, David H.; Barr, Paul; Noy, Ariela.

In: Leukemia and Lymphoma, Vol. 53, No. 12, 01.12.2012, p. 2383-2389.

Research output: Contribution to journalArticle

Bayraktar, UD, Carlos Ramos, J, Petrich, A, Gupta, N, Lensing, S, Moore, PC, Reid, EG, Aboulafia, DM, Ratner, L, Mitsuyasu, R, Cooley, T, Henry, DH, Barr, P & Noy, A 2012, 'Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 19992008 and treated with curative intent in the AIDS Malignancy Consortium', Leukemia and Lymphoma, vol. 53, no. 12, pp. 2383-2389. https://doi.org/10.3109/10428194.2012.697559
Bayraktar, Ulas D. ; Carlos Ramos, Juan ; Petrich, Adam ; Gupta, Neel ; Lensing, Shelly ; Moore, P. C. ; Reid, Erin G. ; Aboulafia, David M. ; Ratner, Lee ; Mitsuyasu, Ronald ; Cooley, Timothy ; Henry, David H. ; Barr, Paul ; Noy, Ariela. / Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 19992008 and treated with curative intent in the AIDS Malignancy Consortium. In: Leukemia and Lymphoma. 2012 ; Vol. 53, No. 12. pp. 2383-2389.
@article{10546712f1984e60ba8ce6f2652ce5fd,
title = "Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 19992008 and treated with curative intent in the AIDS Malignancy Consortium",
abstract = "No comparative studies exist for relapsed/refractory (rel/rfr) acquired immune deficiency syndrome (AIDS)-related lymphoma (ARL). To determine practices over the last decade and to assess the outcomes of salvage chemotherapy with curative intent and autologous stem cell transplant (ASCT), we retrospectively evaluated treatment outcomes in patients with rel/rfr ARL who were treated in 13 national AIDS Malignancy Consortium (AMC) sites between 1999 and 2008 (n 88). The most commonly used second-line therapies were ICE (ifosfamide/carboplatin/ etoposide, n 34), dose adjusted EPOCH (etoposide/prednisone/vincristine/ cyclophosphamide/doxorubicin, n 17) and ESHAP (etoposide/methylprednisolone/ cytarabine/cisplatin, n 11). The odds of achieving a response were lower for those with non-Hodgkin lymphoma (NHL) than for those with HL and for those with primary refractory disease than for those with relapse. Overall survival (OS) was significantly longer for those with relapsed disease compared to those with refractory disease and for those with non-Burkitt NHL compared to those with Burkitt. OS was longer in patients who underwent ASCT compared to those who did not (1-year OS: 63.2{\%} vs. 37.2{\%}). However, among 32 patients (36{\%}) who achieved a complete or partial reponse (CR/PR) after second-line therapy, 1-year OS was not different between the two groups (87.5{\%} for ASCT vs. 81.8{\%} for non-ASCT). Long-term survival in some patients with rel/rfr ARL may be possible without transplant, although transplant remains the standard of care for chemotherapy sensitive disease.",
keywords = "Acquired immune deficiency syndrome, Lymphoma, Salvage therapy, Stem cell transplant",
author = "Bayraktar, {Ulas D.} and {Carlos Ramos}, Juan and Adam Petrich and Neel Gupta and Shelly Lensing and Moore, {P. C.} and Reid, {Erin G.} and Aboulafia, {David M.} and Lee Ratner and Ronald Mitsuyasu and Timothy Cooley and Henry, {David H.} and Paul Barr and Ariela Noy",
year = "2012",
month = "12",
day = "1",
doi = "10.3109/10428194.2012.697559",
language = "English",
volume = "53",
pages = "2383--2389",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "12",

}

TY - JOUR

T1 - Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 19992008 and treated with curative intent in the AIDS Malignancy Consortium

AU - Bayraktar, Ulas D.

AU - Carlos Ramos, Juan

AU - Petrich, Adam

AU - Gupta, Neel

AU - Lensing, Shelly

AU - Moore, P. C.

AU - Reid, Erin G.

AU - Aboulafia, David M.

AU - Ratner, Lee

AU - Mitsuyasu, Ronald

AU - Cooley, Timothy

AU - Henry, David H.

AU - Barr, Paul

AU - Noy, Ariela

PY - 2012/12/1

Y1 - 2012/12/1

N2 - No comparative studies exist for relapsed/refractory (rel/rfr) acquired immune deficiency syndrome (AIDS)-related lymphoma (ARL). To determine practices over the last decade and to assess the outcomes of salvage chemotherapy with curative intent and autologous stem cell transplant (ASCT), we retrospectively evaluated treatment outcomes in patients with rel/rfr ARL who were treated in 13 national AIDS Malignancy Consortium (AMC) sites between 1999 and 2008 (n 88). The most commonly used second-line therapies were ICE (ifosfamide/carboplatin/ etoposide, n 34), dose adjusted EPOCH (etoposide/prednisone/vincristine/ cyclophosphamide/doxorubicin, n 17) and ESHAP (etoposide/methylprednisolone/ cytarabine/cisplatin, n 11). The odds of achieving a response were lower for those with non-Hodgkin lymphoma (NHL) than for those with HL and for those with primary refractory disease than for those with relapse. Overall survival (OS) was significantly longer for those with relapsed disease compared to those with refractory disease and for those with non-Burkitt NHL compared to those with Burkitt. OS was longer in patients who underwent ASCT compared to those who did not (1-year OS: 63.2% vs. 37.2%). However, among 32 patients (36%) who achieved a complete or partial reponse (CR/PR) after second-line therapy, 1-year OS was not different between the two groups (87.5% for ASCT vs. 81.8% for non-ASCT). Long-term survival in some patients with rel/rfr ARL may be possible without transplant, although transplant remains the standard of care for chemotherapy sensitive disease.

AB - No comparative studies exist for relapsed/refractory (rel/rfr) acquired immune deficiency syndrome (AIDS)-related lymphoma (ARL). To determine practices over the last decade and to assess the outcomes of salvage chemotherapy with curative intent and autologous stem cell transplant (ASCT), we retrospectively evaluated treatment outcomes in patients with rel/rfr ARL who were treated in 13 national AIDS Malignancy Consortium (AMC) sites between 1999 and 2008 (n 88). The most commonly used second-line therapies were ICE (ifosfamide/carboplatin/ etoposide, n 34), dose adjusted EPOCH (etoposide/prednisone/vincristine/ cyclophosphamide/doxorubicin, n 17) and ESHAP (etoposide/methylprednisolone/ cytarabine/cisplatin, n 11). The odds of achieving a response were lower for those with non-Hodgkin lymphoma (NHL) than for those with HL and for those with primary refractory disease than for those with relapse. Overall survival (OS) was significantly longer for those with relapsed disease compared to those with refractory disease and for those with non-Burkitt NHL compared to those with Burkitt. OS was longer in patients who underwent ASCT compared to those who did not (1-year OS: 63.2% vs. 37.2%). However, among 32 patients (36%) who achieved a complete or partial reponse (CR/PR) after second-line therapy, 1-year OS was not different between the two groups (87.5% for ASCT vs. 81.8% for non-ASCT). Long-term survival in some patients with rel/rfr ARL may be possible without transplant, although transplant remains the standard of care for chemotherapy sensitive disease.

KW - Acquired immune deficiency syndrome

KW - Lymphoma

KW - Salvage therapy

KW - Stem cell transplant

UR - http://www.scopus.com/inward/record.url?scp=84868379222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868379222&partnerID=8YFLogxK

U2 - 10.3109/10428194.2012.697559

DO - 10.3109/10428194.2012.697559

M3 - Article

C2 - 22642936

AN - SCOPUS:84868379222

VL - 53

SP - 2383

EP - 2389

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 12

ER -